# EDGAR Filing Document

**Accession Number:** 0001937011
**File Stem:** 0001315863-25-000444
**Filing Date:** 2025-6
**Character Count:** 11611
**Document Hash:** a580e1c470811406f5c178f8e1a93a06
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001315863-25-000444.hdr.sgml**: 20250605

**ACCESSION NUMBER**: 0001315863-25-000444

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250605

**DATE AS OF CHANGE**: 20250605

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** PROKIDNEY CORP.
- **CENTRAL INDEX KEY:** 0001850270
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 981586514
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-92651
- **FILM NUMBER:** 251027342

**BUSINESS ADDRESS:**
- **STREET 1:** 2000 FRONTIS PLAZA BLVD.
- **STREET 2:** SUITE 250
- **CITY:** WINSTON-SALEM
- **STATE:** NC
- **ZIP:** 27103
- **BUSINESS PHONE:** 336-999-7028

**MAIL ADDRESS:**
- **STREET 1:** 2000 FRONTIS PLAZA BLVD.
- **STREET 2:** SUITE 250
- **CITY:** WINSTON-SALEM
- **STATE:** NC
- **ZIP:** 27103

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Social Capital Suvretta Holdings Corp. III
- **DATE OF NAME CHANGE:** 20210310
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Tolerantia, LLC
- **CENTRAL INDEX KEY:** 0001937011

**ORGANIZATION NAME:**
- **EIN:** 824989989
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**BUSINESS ADDRESS:**
- **STREET 1:** 110 EAST 59TH STREET
- **STREET 2:** SUITE 3300
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10022
- **BUSINESS PHONE:** 212-883-8033

**MAIL ADDRESS:**
- **STREET 1:** 110 EAST 59TH STREET
- **STREET 2:** SUITE 3300
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10022

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 5)**

**ProKidney Corp.**

*(Name of Issuer)*

**Class A ordinary shares, par value $0.0001 per share**

*(Title of Class of Securities)*

**G7S53R104**

*(CUSIP Number)*

**Tolerantia, LLC**<br>110 East 59th Street, Suite 2800<br>New York NY 10022<br>(212) 883-0200

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**06/03/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **G7S53R104** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Tolerantia, LLC** | Name of reporting person<br>**Tolerantia, LLC** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**106901339.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**106901339.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**106901339.00** | Aggregate amount beneficially owned by each reporting person<br>**106901339.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**36.5%** | Percent of class represented by amount in Row (11)<br>**36.5%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

| **CUSIP No.** | **G7S53R104** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Pablo Legorreta** | Name of reporting person<br>**Pablo Legorreta** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**106901339.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**106901339.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**106901339.00** | Aggregate amount beneficially owned by each reporting person<br>**106901339.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**36.5%** | Percent of class represented by amount in Row (11)<br>**36.5%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Class A ordinary shares, par value $0.0001 per share

**(b) Name of Issuer:**
ProKidney Corp.

**(c) Address of Issuer's Principal Executive Offices:**
2000 Frontis Plaza Blvd., Suite 250, Winston-Salem, NC, 27103

This Amendment No. 5 to Schedule 13D amends and supplements the Schedule 13D filed by the undersigned with the Securities and Exchange Commission (the "SEC") on July 22, 2022, as amended and supplemented on November 2, 2023, February 6, 2024, June 14, 2024, and February 6, 2025 (collectively, the "Schedule 13D"). All capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Schedule 13D.

**Item 5. Interest in Securities of the Issuer**

**(a)**
Tolerantia, LLC:

Amount beneficially owned: 106,901,339
Percent of Class: 36.5% based on the number of Class A ordinary shares, $0.0001 par value (the "Class A ordinary shares"), and Class B ordinary shares, $0.0001 par value (the "Class B ordinary shares"), of ProKidney Corp. (the "Issuer") outstanding on a combined basis and 49.1% based solely on the outstanding Class A ordinary shares and the Class A ordinary shares issuable upon the conversion of Class B ordinary shares and the exchange of the common units (the "Common Units") beneficially owned by Tolerantia, LLC ("Tolerantia") as set forth below

Pablo Legorreta:

Amount beneficially owned: 106,901,339
Percent of Class: 36.5% based on the number of Class A ordinary shares and Class B ordinary shares outstanding on a combined basis and 49.1% based on the outstanding Class A ordinary shares and the Class A ordinary shares issuable upon the conversion of Class B ordinary shares and the exchange of the Common Units held by or for the benefit of Tolerantia, which are deemed to be beneficially owned by Mr. Legorreta as set forth below

**(b)**
Tolerantia, LLC:

Number of shares the Reporting Person has:
Sole power to vote or direct the vote: 0
Shared power to vote: 106,901,339
Sole power to dispose or direct the disposition of: 0
Shared power to dispose or direct the disposition of: 106,901,339

Pablo Legorreta:

Number of shares the Reporting Person has:	 
Sole power to vote or direct the vote: 0
Shared power to vote: 106,901,339
Sole power to dispose or direct the disposition of: 0
Shared power to dispose or direct the disposition of: 106,901,339

106,901,339 shares represent 22,617,909 Class A ordinary shares and 84,283,430 Class B ordinary shares held by or for the benefit of Tolerantia, which is an affiliate controlled and majority-owned by Mr. Pablo Legorreta. Mr. Legorreta controls the voting and disposition of the shares held by or for the benefit of Tolerantia. Mr. Legorreta disclaims beneficial ownership of the shares held by Tolerantia except to the extent of his indirect pecuniary interest therein.

The aggregate percentage of Class A ordinary shares reported as beneficially owned by each Reporting Person is based upon a total of 292,703,024 shares, comprising 133,360,117 Class A ordinary shares and 159,342,907 Class B ordinary shares outstanding as of May 12, 2025, which is the total number of shares outstanding as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 12, 2025, as adjusted for the conversion set forth in 5(c) below. The Reporting Persons have the right to exchange their Common Units and an equal number of Class B ordinary shares on a one-for-one basis for Class A ordinary shares. The applicable SEC rules generally attribute beneficial ownership of securities to persons who possess sole or shared voting power or investment power with respect to those securities and include Class A ordinary shares issuable upon the conversion or exercise of other securities that are immediately convertible or exercisable, or are convertible or exercisable within 60 days of the filing of this Schedule 13D.

**(c)**
Prior to June 3, 2025 (the "Transaction Date"), Tolerantia held 88,107,426 Common Units and an equal number of Class B ordinary shares (the "Paired Interests"), 84,160,537 of which were held by Nefro Health, an Irish partnership that is an affiliate controlled and majority-owned by Mr. Pablo Legorreta, and 3,946,889 of which were held by other investors which are unaffiliated with Mr. Legorreta (the "Unaffiliated Investors"). On the Transaction Date, Tolerantia exchanged 3,823,996 of the 3,946,889 Paired Interests attributable to the interests of the Unaffiliated Investors in Tolerantia for 3,823,996 Class A ordinary shares, which it subsequently distributed in-kind pro rata for no consideration to the Unaffiliated Investors.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Tolerantia, LLC

**Signature:** /s/ Jaime Gomez-Sotomayor

**Name/Title:** Jaime Gomez-Sotomayor / Authorized Signatory

**Date:** 06/05/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Pablo Legorreta

**Signature:** /s/ Pablo Legorreta

**Name/Title:** Pablo Legorreta / Self

**Date:** 06/05/2025